Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Drugs in Development, 2021
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Drugs in Development, 2021
SUMMARY
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) pipeline Target constitutes close to 42 molecules. Out of which approximately 39 molecules are developed by companies and remaining by the universities/institutes. The latest report Cyclin Dependent Kinase 4 - Drugs in Development, 2021, outlays comprehensive information on the Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Cyclin-dependent kinase 4 is an enzyme encoded by the CDK4 gene. Ser/Thr-kinase component of cyclin D-CDK4 (DC) complexes phosphorylate and inhibit members of the retinoblastoma (RB) protein family including RB1 and regulate the cell-cycle during G1/S transition. Activation of the cyclin-D-CDK4 complex appears to require other factors such as recruitment of the substrate via a substrate recruitment motif, and/or formation of the CDKN1B ternary complex.
The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 4, 7, 10, 2, 11 and 4 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease, Toxicology, Cardiovascular, Genetic Disorders and Metabolic Disorders which include indications Metastatic Breast Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Solid Tumor, Mantle Cell Lymphoma, Triple-Negative Breast Cancer (TNBC), Colorectal Cancer, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Esophageal Cancer, Gastric Cancer, Glioblastoma Multiforme (GBM), Metastatic Colorectal Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Prostate Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Colon Cancer, Fallopian Tube Cancer, Head And Neck Cancer, Hepatocellular Carcinoma, Liposarcoma, Lymphoma, Pancreatic Cancer, Pediatric Diffuse Intrinsic Pontine Glioma, Peritoneal Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Bladder Cancer, Chemotherapy Induced Myelosuppression, Dedifferentiated Liposarcoma, Diffuse Large B-Cell Lymphoma, Epithelial Ovarian Cancer, High-Grade Glioma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Leukemia, Melanoma, Metastatic Brain Tumor, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Melanoma, Metastatic Ovarian Cancer, Neuroblastoma, Neuroendocrine Tumors, Oligodendroglioma, Recurrent Glioblastoma Multiforme (GBM), Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Thymic Carcinoma, Adenocarcinoma Of The Gastroesophageal Junction, AIDS - Related Cancer, Anaplastic Oligoastrocytoma, Astrocytoma, Bile Duct Cancer (Cholangiocarcinoma), Brain Cancer, Brain Tumor, Central Nervous System (CNS) Tumor, Cervical Cancer, Chordoma, Chronic Lymphocytic Leukemia (CLL), Ductal Carcinoma In Situ, Duodenal Cancer, Ependymoma, Epstein-Barr Virus (HHV-4) Infections, Esophageal Squamous Cell Carcinoma (ESCC), Ewing Sarcoma, Follicular Lymphoma, Hormone Sensitive Breast Cancer, Human Immunodeficiency Virus (HIV) Infections (AIDS), Hypopharyngeal Cancer, Kidney Cancer (Renal Cell Cancer), Laryngeal Cancer, Malignant Mesothelioma, Marginal Zone B-cell Lymphoma, Medulloblastoma, Meningioma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Biliary Tract Cancer, Metastatic Pancreatic Cancer, Metastatic Renal Cell Carcinoma, Multiple Myeloma (Kahler Disease), Neurofibromatoses Type I (Von Recklinghausen’s Disease), Nonmelanomatous Skin Cancer, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Pancreatic Ductal Adenocarcinoma, Primary CNS Lymphoma, Pulmonary Arterial Hypertension, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia (CLL), Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Chronic Lymphocytic Leukemia (CLL), Relapsed Multiple Myeloma, Rhabdomyosarcoma, Small-Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer, Thymoma (Thymic Epithelial Tumor), Thyroid Cancer, Transitional Cell Cancer (Urothelial Cell Cancer), Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Type 2 Diabetes and Well Differentiated Liposarcoma.
Furthermore, this report also reviews key players involved in Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) pipeline Target constitutes close to 42 molecules. Out of which approximately 39 molecules are developed by companies and remaining by the universities/institutes. The latest report Cyclin Dependent Kinase 4 - Drugs in Development, 2021, outlays comprehensive information on the Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Cyclin-dependent kinase 4 is an enzyme encoded by the CDK4 gene. Ser/Thr-kinase component of cyclin D-CDK4 (DC) complexes phosphorylate and inhibit members of the retinoblastoma (RB) protein family including RB1 and regulate the cell-cycle during G1/S transition. Activation of the cyclin-D-CDK4 complex appears to require other factors such as recruitment of the substrate via a substrate recruitment motif, and/or formation of the CDKN1B ternary complex.
The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 4, 7, 10, 2, 11 and 4 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease, Toxicology, Cardiovascular, Genetic Disorders and Metabolic Disorders which include indications Metastatic Breast Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Solid Tumor, Mantle Cell Lymphoma, Triple-Negative Breast Cancer (TNBC), Colorectal Cancer, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Esophageal Cancer, Gastric Cancer, Glioblastoma Multiforme (GBM), Metastatic Colorectal Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Prostate Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Colon Cancer, Fallopian Tube Cancer, Head And Neck Cancer, Hepatocellular Carcinoma, Liposarcoma, Lymphoma, Pancreatic Cancer, Pediatric Diffuse Intrinsic Pontine Glioma, Peritoneal Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Bladder Cancer, Chemotherapy Induced Myelosuppression, Dedifferentiated Liposarcoma, Diffuse Large B-Cell Lymphoma, Epithelial Ovarian Cancer, High-Grade Glioma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Leukemia, Melanoma, Metastatic Brain Tumor, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Melanoma, Metastatic Ovarian Cancer, Neuroblastoma, Neuroendocrine Tumors, Oligodendroglioma, Recurrent Glioblastoma Multiforme (GBM), Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Thymic Carcinoma, Adenocarcinoma Of The Gastroesophageal Junction, AIDS - Related Cancer, Anaplastic Oligoastrocytoma, Astrocytoma, Bile Duct Cancer (Cholangiocarcinoma), Brain Cancer, Brain Tumor, Central Nervous System (CNS) Tumor, Cervical Cancer, Chordoma, Chronic Lymphocytic Leukemia (CLL), Ductal Carcinoma In Situ, Duodenal Cancer, Ependymoma, Epstein-Barr Virus (HHV-4) Infections, Esophageal Squamous Cell Carcinoma (ESCC), Ewing Sarcoma, Follicular Lymphoma, Hormone Sensitive Breast Cancer, Human Immunodeficiency Virus (HIV) Infections (AIDS), Hypopharyngeal Cancer, Kidney Cancer (Renal Cell Cancer), Laryngeal Cancer, Malignant Mesothelioma, Marginal Zone B-cell Lymphoma, Medulloblastoma, Meningioma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Biliary Tract Cancer, Metastatic Pancreatic Cancer, Metastatic Renal Cell Carcinoma, Multiple Myeloma (Kahler Disease), Neurofibromatoses Type I (Von Recklinghausen’s Disease), Nonmelanomatous Skin Cancer, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Pancreatic Ductal Adenocarcinoma, Primary CNS Lymphoma, Pulmonary Arterial Hypertension, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia (CLL), Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Chronic Lymphocytic Leukemia (CLL), Relapsed Multiple Myeloma, Rhabdomyosarcoma, Small-Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer, Thymoma (Thymic Epithelial Tumor), Thyroid Cancer, Transitional Cell Cancer (Urothelial Cell Cancer), Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Type 2 Diabetes and Well Differentiated Liposarcoma.
Furthermore, this report also reviews key players involved in Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22)
- The report reviews Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics and enlists all their major and minor projects
- The report assesses Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Overview
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Therapeutics Development
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Therapeutics Assessment
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Companies Involved in Therapeutics Development
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Drug Profiles
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Dormant Products
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Discontinued Products
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Product Development Milestones
Appendix
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Overview
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Therapeutics Development
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Therapeutics Assessment
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Companies Involved in Therapeutics Development
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Drug Profiles
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Dormant Products
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Discontinued Products
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Product Development Milestones
Appendix
LIST OF TABLES
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indications, 2021
Number of Products under Development by Indications, 2021 (Contd..1)
Number of Products under Development by Indications, 2021 (Contd..2)
Number of Products under Development by Indications, 2021 (Contd..3)
Number of Products under Development by Indications, 2021 (Contd..4)
Number of Products under Development by Companies, 2021
Number of Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Products under Development by Companies, 2021 (Contd..3)
Products under Development by Companies, 2021 (Contd..4)
Products under Development by Companies, 2021 (Contd..5)
Products under Development by Companies, 2021 (Contd..6)
Products under Development by Companies, 2021 (Contd..7)
Products under Development by Companies, 2021 (Contd..8)
Products under Development by Companies, 2021 (Contd..9)
Products under Development by Companies, 2021 (Contd..10)
Products under Development by Companies, 2021 (Contd..11)
Products under Development by Companies, 2021 (Contd..12)
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Aucentra Therapeutics Pty Ltd, 2021
Pipeline by Beta Pharma Inc, 2021
Pipeline by Betta Pharmaceuticals Co Ltd, 2021
Pipeline by CStone Pharmaceuticals Co Ltd, 2021
Pipeline by Eli Lilly and Co, 2021
Pipeline by ESSA Pharma Inc, 2021
Pipeline by Fochon Pharmaceutical Ltd, 2021
Pipeline by G1 Therapeutics Inc, 2021
Pipeline by Guangzhou BeBetter Medicine Technology Co Ltd, 2021
Pipeline by HEC Pharm Co Ltd, 2021
Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, 2021
Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2021
Pipeline by MEI Pharma Inc, 2021
Pipeline by Novartis AG, 2021
Pipeline by Nuvation Bio Inc, 2021
Pipeline by Onconova Therapeutics Inc, 2021
Pipeline by Pfizer Inc, 2021
Pipeline by Rizen (Suzhou) Biosciences Co Ltd, 2021
Pipeline by Sanofi, 2021
Pipeline by SATT Conectus Alsace SAS, 2021
Pipeline by Shanghai Haihe Biopharma Co Ltd, 2021
Pipeline by Shanghai Haishi Biopharmaceutical Co Ltd, 2021
Pipeline by Shanghai Junshi Bioscience Co Ltd, 2021
Pipeline by Shanghai Pharmaceutical Group Co Ltd, 2021
Pipeline by Shanghai Xunhe Pharmaceutical Technology Co Ltd, 2021
Pipeline by Shengke Pharmaceuticals (Jiangsu) Ltd, 2021
Pipeline by SignalRx Pharmaceuticals Inc, 2021
Pipeline by Sihuan Pharmaceutical Holdings Group Ltd, 2021
Pipeline by Sino Biopharmaceutical Ltd, 2021
Pipeline by Tetranov International Inc, 2021
Pipeline by Tiziana Life Sciences Plc, 2021
Pipeline by ViroStatics SRL, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Dormant Products, 2021 (Contd..2)
Discontinued Products, 2021
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indications, 2021
Number of Products under Development by Indications, 2021 (Contd..1)
Number of Products under Development by Indications, 2021 (Contd..2)
Number of Products under Development by Indications, 2021 (Contd..3)
Number of Products under Development by Indications, 2021 (Contd..4)
Number of Products under Development by Companies, 2021
Number of Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Products under Development by Companies, 2021 (Contd..3)
Products under Development by Companies, 2021 (Contd..4)
Products under Development by Companies, 2021 (Contd..5)
Products under Development by Companies, 2021 (Contd..6)
Products under Development by Companies, 2021 (Contd..7)
Products under Development by Companies, 2021 (Contd..8)
Products under Development by Companies, 2021 (Contd..9)
Products under Development by Companies, 2021 (Contd..10)
Products under Development by Companies, 2021 (Contd..11)
Products under Development by Companies, 2021 (Contd..12)
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Aucentra Therapeutics Pty Ltd, 2021
Pipeline by Beta Pharma Inc, 2021
Pipeline by Betta Pharmaceuticals Co Ltd, 2021
Pipeline by CStone Pharmaceuticals Co Ltd, 2021
Pipeline by Eli Lilly and Co, 2021
Pipeline by ESSA Pharma Inc, 2021
Pipeline by Fochon Pharmaceutical Ltd, 2021
Pipeline by G1 Therapeutics Inc, 2021
Pipeline by Guangzhou BeBetter Medicine Technology Co Ltd, 2021
Pipeline by HEC Pharm Co Ltd, 2021
Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, 2021
Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2021
Pipeline by MEI Pharma Inc, 2021
Pipeline by Novartis AG, 2021
Pipeline by Nuvation Bio Inc, 2021
Pipeline by Onconova Therapeutics Inc, 2021
Pipeline by Pfizer Inc, 2021
Pipeline by Rizen (Suzhou) Biosciences Co Ltd, 2021
Pipeline by Sanofi, 2021
Pipeline by SATT Conectus Alsace SAS, 2021
Pipeline by Shanghai Haihe Biopharma Co Ltd, 2021
Pipeline by Shanghai Haishi Biopharmaceutical Co Ltd, 2021
Pipeline by Shanghai Junshi Bioscience Co Ltd, 2021
Pipeline by Shanghai Pharmaceutical Group Co Ltd, 2021
Pipeline by Shanghai Xunhe Pharmaceutical Technology Co Ltd, 2021
Pipeline by Shengke Pharmaceuticals (Jiangsu) Ltd, 2021
Pipeline by SignalRx Pharmaceuticals Inc, 2021
Pipeline by Sihuan Pharmaceutical Holdings Group Ltd, 2021
Pipeline by Sino Biopharmaceutical Ltd, 2021
Pipeline by Tetranov International Inc, 2021
Pipeline by Tiziana Life Sciences Plc, 2021
Pipeline by ViroStatics SRL, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Dormant Products, 2021 (Contd..2)
Discontinued Products, 2021
LIST OF FIGURES
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
